Hair loss is listed as a common adverse reaction in Wegovy's current U.S. prescribing information.[5] A new 2026 study adds a genetic signal related to male-pattern baldness, but it did not follow people taking Wegovy (semaglutide), a GLP-1 medication.[1][2] The result is not a direct estimate of how often patients lose hair during treatment.[1][3]
What the new study looked at
Published online in September 2026, the study used two-sample Mendelian randomization, a method that uses genetic variation to test whether an exposure may be linked to an outcome.[1][2] Researchers used genetic variants associated with GLP1R expression as a proxy for GLP-1 receptor activity and compared them with genetic data on androgenetic alopecia, the inherited pattern often called male-pattern baldness.[1][2]
One dataset contained 31,684 mostly White men and women; the hair-loss outcome dataset contained 205,327 mostly White men.[1] Because that outcome was measured in men, the study does not establish whether the same association applies to women.[1]
The study's main estimate was an odds ratio of 1.07, or about 7% higher odds in the genetic analysis.[3] That does not mean seven more people out of every hundred will lose their hair, nor does it give an individual's chance of hair loss while taking semaglutide.[1][3] The study did not test a Wegovy dose or compare patients who started the medicine with patients who did not.[1][2]
Why a genetic finding is not the same as taking Wegovy
The genetic analysis reflects inherited differences in GLP1R expression over a lifetime.[3] Starting a prescription drug later in life is a different exposure, so the estimate cannot be converted into a medication-specific risk.[3] The researchers used expression data from blood, not measurements from scalp or hair follicles.[3]
The authors described the estimate as modest and its clinical relevance as uncertain.[3] The association also concerns androgenetic alopecia, not every kind of shedding or hair loss.[1][3] The result cannot show why one person is losing hair, whether one dose is riskier than another, or whether the same finding applies to women.[1][3]
Another study examined people using GLP-1 medications
A July 2026 BMJ study used health records from adults with type 2 diabetes and compared new users of GLP-1 receptor agonists with new users of SGLT-2 or DPP-4 inhibitors.[4] It reported higher adjusted hazards of a recorded alopecia diagnosis for GLP-1 users than for SGLT-2 inhibitor users (hazard ratio 1.37, 95% CI 1.08 to 1.73) or DPP-4 inhibitor users (1.68, 95% CI 1.28 to 2.20).[4]
Those are relative estimates, not the percentage of patients who lost hair.[4] The study was observational, and its results weakened after negative-control calibration.[4] It examined adults with type 2 diabetes and GLP-1 medicines as a group; it did not isolate Wegovy or prove that a specific medicine caused the recorded hair loss.[4]
The studies answer different questions: one examined genetic proxies and male-pattern baldness, while the other examined recorded diagnoses among adults with type 2 diabetes taking GLP-1 medicines.[1][4] Neither gives a personal prediction for someone considering or using Wegovy.[1][4]
What the Wegovy information says
The current U.S. prescribing information lists hair loss among common adverse reactions reported in clinical trials.[5] That makes hair loss worth discussing with a prescriber, but the label does not identify the cause of an individual's symptoms.[5]
Hair shedding and patterned hair loss are not interchangeable terms, and one person can have more than one cause.[8] The American Academy of Dermatology says a dermatologist can help distinguish excessive shedding from other forms of hair loss.[8] If you notice new or worsening hair loss, tell your clinician when it began and mention recent medication, illness, or weight changes.[8] Do not stop or change a prescription on your own; contact the prescriber first.[5][8]
Bottom line
The 2026 genetic study is a modest signal about male-pattern hair loss, not proof that Wegovy causes baldness.[1][3] The prescribing information and a separate observational study add context, but neither can diagnose the cause of a person's hair loss.[4][5] A dermatologist or prescriber can help distinguish shedding from patterned loss and discuss what to do next.[8]
This article is for informational purposes only and is not medical advice. Talk with your prescriber before changing a prescription medicine.
